Trial Profile
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy: A multicenter, placebo-controlled, double-blind, randomized study in Japanese gynecologic patients receiving paclitaxel and carboplatin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Mar 2015
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone; Serotonin 3 receptor antagonists
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Therapeutic Use
- 31 Mar 2015 New trial record